Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

NCT05312476 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG: Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

Sponsor

The First Affiliated Hospital of Soochow University